|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.90 EUR | +3.62% |
|
+3.62% | +7.51% |
| 12/01 | Fagron Concludes Purchase of US-based University Compounding Pharmacy | MT |
| 12/01 | Fagron completes $41.5 million acquisition in North America | RE |
| Capitalization | 167.73Cr 194.55Cr 156.14Cr 145.36Cr 270.64Cr 18TCr 291.19Cr 1.8TCr 708.2Cr 8.42TCr 729.6Cr 714.58Cr 31TCr | P/E ratio 2025 * |
18x | P/E ratio 2026 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise value | 196.21Cr 227.6Cr 182.66Cr 170.05Cr 316.61Cr 21TCr 340.65Cr 2.1TCr 828.48Cr 9.85TCr 853.52Cr 835.95Cr 36TCr | EV / Sales 2025 * |
2.08x | EV / Sales 2026 * | 1.92x |
| Free-Float |
94.54% | Yield 2025 * |
1.72% | Yield 2026 * | 1.9% |
Last Transcript: Fagron N.V.
| 1 day | +3.62% | ||
| 1 week | +3.62% | ||
| Current month | +7.51% | ||
| 1 month | +11.44% | ||
| 3 months | +10.90% | ||
| 6 months | +5.53% | ||
| Current year | +7.51% |
| 1 week | 21.55 |  | 23 |
| 1 month | 20.7 | | 23 |
| Current year | 21.55 | | 23 |
| 1 year | 17.54 | | 23.5 |
| 3 years | 12.97 | | 23.5 |
| 5 years | 10.8 | | 23.5 |
| 10 years | 4.08 | | 23.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 27/11/2017 | |
Karin de Jong
DFI | Director of Finance/CFO | 47 | 01/05/2016 |
Vera Bakker
COO | Chief Operating Officer | 54 | 09/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Karin de Jong
BRD | Director/Board Member | 47 | 01/05/2016 |
Koen Hoffman
CHM | Chairman | 58 | 09/05/2017 |
| Director/Board Member | 48 | 07/02/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.62% | +3.62% | +34.23% | +62.64% | 194.55Cr | |
| +0.53% | -2.37% | +43.09% | +190.27% | 93TCr | |
| -0.41% | +6.98% | +48.72% | +26.86% | 53TCr | |
| -0.31% | -2.60% | +24.94% | +40.25% | 38TCr | |
| +0.93% | +2.38% | +31.46% | +18.47% | 37TCr | |
| +0.19% | -1.15% | +28.47% | +21.14% | 29TCr | |
| +0.98% | +1.37% | +29.42% | +35.03% | 28TCr | |
| -1.93% | -1.54% | +11.14% | -1.47% | 27TCr | |
| +6.49% | +1.95% | -32.44% | -18.44% | 27TCr | |
| +0.12% | +1.32% | +21.43% | +22.64% | 18TCr | |
| Average | +1.02% | +1.00% | +24.05% | +39.74% | 34.93TCr | |
| Weighted average by Cap. | +0.60% | +0.51% | +29.05% | +65.22% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 94Cr 109.28Cr 88Cr 82Cr 152.02Cr 9.92TCr 163.56Cr 1.01TCr 397.78Cr 4.73TCr 409.8Cr 401.37Cr 17TCr | 102.92Cr 119.38Cr 96Cr 89Cr 166.07Cr 11TCr 178.67Cr 1.1TCr 434.55Cr 5.17TCr 447.68Cr 438.47Cr 19TCr |
| Net income | 9.38Cr 11Cr 8.74Cr 8.13Cr 15Cr 987.74Cr 16Cr 100.5Cr 40Cr 471.15Cr 41Cr 40Cr 1.72TCr | 11Cr 13Cr 10Cr 9.49Cr 18Cr 1.15TCr 19Cr 117.28Cr 46Cr 549.84Cr 48Cr 47Cr 2.01TCr |
| Net Debt | 28Cr 33Cr 27Cr 25Cr 46Cr 3TCr 49Cr 305.05Cr 120.29Cr 1.43TCr 123.92Cr 121.37Cr 5.22TCr | 30Cr 34Cr 28Cr 26Cr 48Cr 3.12TCr 51Cr 317.46Cr 125.18Cr 1.49TCr 128.96Cr 126.31Cr 5.43TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | 22.90 € | +3.62% | 1,39,396 |
| 15/26/15 | 22.10 € | +1.61% | 1,42,164 |
| 14/26/14 | 21.75 € | 0.00% | 1,01,651 |
| 13/26/13 | 21.75 € | -1.14% | 1,17,514 |
| 12/26/12 | 22.00 € | -0.45% | 69,984 |
Real-time Euronext Bruxelles, January 16, 2026 at 10:25 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- FAGR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition